GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » BioLargo Inc (OTCPK:BLGO) » Definitions » Preferred Stock

BioLargo (BioLargo) Preferred Stock : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 1991. Start your Free Trial

What is BioLargo Preferred Stock?

Preferred stock is a special equity security that has properties of both equity and debt. BioLargo's preferred stock for the quarter that ended in Mar. 2024 was $0.00 Mil.

The market value of preferred stock needs to be added to the market value of common stocks in the calculation of Enterprise Value. BioLargo's Enterprise Value for the quarter that ended in Mar. 2024 was $99.25 Mil.

In the calculation of book value, the par value of preferred stocks needs to subtracted from total equity. BioLargo's Book Value per Share for the quarter that ended in Mar. 2024 was $0.03.

Dividends paid to preferred stocks need to be subtracted from net income in the calculation of Earnings per Share (Diluted). BioLargo's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-0.00.


BioLargo Preferred Stock Historical Data

The historical data trend for BioLargo's Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLargo Preferred Stock Chart

BioLargo Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Preferred Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BioLargo Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Preferred Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

BioLargo Preferred Stock Calculation

Preferred Stock is a special equity security that has properties of both equity and debt. It is generally considered a hybrid instrument. Preferred stock is senior to common stock, but is subordinate to bonds in terms of claim or rights to their share of the assets of the company.

Preferred stock has priority over common stock in the payment of dividends and any payments received when a company liquidates.

Preferred stock comes in many forms. It can be:


Convertible or Non-Convertible
Cumulative or Non-Cumulative
Voting or Non-Voting
Callable or Non-Callable
Maturity Date or No Maturity Date

A preferred stock without a maturity date is called a perpetual preferred stock. These are relatively rare. A good example of perpetual preferred stock is the many series of Public Storage (PSA) preferred shares that trade on the New York Stock Exchange.

Before investing in preferred stock, it is important to know which of the above groups the stock belongs to. Is it convertible or non-convertible? Are dividends cumulative or non-cumulative?

It is also critical that an investor knows what bonds the company has in front of the preferred stock. Bondholders get paid first. So the decision to buy a preferred stock can be similar to the decision to buy a bond. But, remember, the preferred stock of a company with bonds is junior to those bonds.

Unless a preferred stock is convertible, the upside in a preferred stock investment is more limited than in a common stock investment. If a company doubles its earnings, it is usually under no more obligation to double the dividends paid to preferred shareholders than it is to double the interest paid to its bankers and bondholders.So preferred stock is very different from common stock.


BioLargo  (OTCPK:BLGO) Preferred Stock Explanation

When a company needs capital but does not wish to issue debt, they may sell preferred stocks to investors.

For instance, during the financial crisis of 2008, Goldman Sachs (GS) issued a combination of preferred stock and common stock options for $5 billion of capital to Warren Buffett’s Berkshire Hathaway (BRK.A)(BRK.B). In this deal, Berkshire Hathaway paid $5 billion for 10% cumulative perpetual preferred stock and warrants to buy 43.5 million shares of Goldman Sachs at $115 a share. Goldman Sachs bought back the preferred in 2010. Guess how much money Warren Buffett made in this deal in two years? Read How Much Did Warren Buffett’s Berkshire Hathaway (BRK.B) Make on Its Goldman Sachs (GS) Preferred Stock?

1. The market value of Preferred Stocks needs to be added to the market value of common stocks in the calculation of enterprise value.

BioLargo's Enterprise Value for the quarter that ended in Mar. 2024 is calculated as

2. In the calculation of Book Value, the par value of Preferred Stocks needs to subtracted from total equity.

BioLargo's Book Value per Share for the quarter that ended in Mar. 2024 is calculated as

3. Dividends paid to Preferred Stocks need to be subtracted from net income in the calculation of earnings per share.

BioLargo's Earnings per Share (Diluted) (EPS) for the three months ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioLargo Preferred Stock Related Terms

Thank you for viewing the detailed overview of BioLargo's Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.


BioLargo (BioLargo) Business Description

Traded in Other Exchanges
N/A
Address
14921 Chestnut Street, Westminster, CA, USA, 92683
BioLargo Inc invents, develops, and commercializes platform technologies to solve challenging environmental problems like PFAS contamination, advanced water, and wastewater treatment, industrial odor, and VOC control, air quality control, and infection control. The company holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. BioLargo invents or acquires novel technologies and develops them to maturity through its operating subsidiaries. It monetizes through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation, and/or the sale of the IP. The firm's technologies are commercially available and are advancing as disrupters in their respective markets.
Executives
Linda Park director 14921 CHESTNUT STREET, WESTMINSTER CA 92683
Christina Elaine Bray director PO BOX 234, FREDERICK CO 80530
Jack B. Strommen director 7108 31ST AVENUE N., MINNEAPOLIS MN 55427
Roberts Kent Charles Ii director 1146 OXFORD ROAD, SAN MARINO CA 91108
John S. Runyan director 30001 HILLSIDE TERRACE, SAN JUAN CAPISTRANO CA 92675
Dennis E Marshall director 3500 W. GARRY AVENUE, SANTA ANA CA 92705
Dennis P Calvert director, 10 percent owner, officer: Chief Executive Officer 3500 GARRY AVE, SANTA ANA CA 92704
New Millennium Capital Partners, Llc 10 percent owner 16333 PHOEBE AVENUE, LA MIRADA CA 90638
Charles K Dargan officer: Chief Financial Officer 8055 W. MANCHESTER AVE., SUITE 405, PLAYA DEL REY CA 90293
Joseph L Provenzano director, officer: Corporate Secretary 3500 W. GARRY AVENUE, SANTA ANA CA 92704
Iowc Technologies, Inc. 10 percent owner 2603 MAIN STREET, SUITE 1155, IRVINE CA 92614
Kenneth Reay Code 10 percent owner 16150 HERON AVENUE, LA MIRADA CA 90638
Gary Adrian Cox director 3500 W. GARRY AVENUE, SANTA ANA CA 92705
Steven V Harrison director
Eduardo Ruiz director, 10 percent owner